Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03889093 · ClinicalTrials.gov registry record · NA
Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System
A NA study, sponsored by University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03889093: Clinical Trial NA study, sponsored by University of Minnesota.
NCT03889093 is a NA study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03889093, a NA study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The goal of this study is to understand the immunologic effects radioembolization has on the immune system. This will be done by evaluating the changes on biopsy, peripheral blood monocytes, and cytokines.
Primary Outcome
Determine changes in the peripheral blood lymphocytes utilizing flow cytometery after radioembolization (RE) therapy for primary and secondary malignancies of the liver at 12 weeks.
Interventions
- OTHER Yttrium-90
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-08-09 |
| Est. Completion | 2022-02-24 |
| Phase | NA |
Why NCT03889093 stopped before completion
NCT03889093 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Yttrium-90 is the first listed.
NCT03889093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03889093 about?
NCT03889093 is a clinical study titled "Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System". The goal of this study is to understand the immunologic effects radioembolization has on the immune system. This will be done by evaluating the changes on biopsy, peripheral blood monocytes, and cytokines.
What is the current status of trial NCT03889093?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2018-08-09. Estimated completion is 2022-02-24.
What interventions are being tested in trial NCT03889093?
The interventions under investigation include: Yttrium-90 (OTHER).
Who is sponsoring clinical trial NCT03889093?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03889093's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy